Life Science Investing Tenax Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update
Life Science Investing Tenax Therapeutics to Host Virtual KOL Call to Discuss TNX-103 for the Treatment of PH-HFpEF
Life Science Investing Tenax Therapeutics to Participate in the Guggenheim 2nd Annual Healthcare Innovation Conference
Life Science Investing Tenax Therapeutics Announces European Patent Office Intention to Grant Patent Covering Use of Levosimendan in PH-HFpEF
Life Science Investing Tenax Therapeutics to Participate in the Cantor Global Healthcare Conference 2025
Life Science Investing Tenax Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update
Momentum Builds, Upside Appears as Mining Explorers Transition Toward Production, Unlock Major Hidden Value
Romios Proposes Name Change and Share Consolidation, Annual General and Special Meeting Scheduled for January 16, 2026
